1. Home
  2. JTAI vs BGLC Comparison

JTAI vs BGLC Comparison

Compare JTAI & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

N/A

Current Price

$1.19

Market Cap

6.8M

Sector

Finance

ML Signal

N/A

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$4.05

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JTAI
BGLC
Founded
2018
2017
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Blank Checks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8M
10.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
BGLC
Price
$1.19
$4.05
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
120.9K
201.9K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,584,279.00
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
$433.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$1.15
$2.01
52 Week High
$11.77
$15.60

Technical Indicators

Market Signals
Indicator
JTAI
BGLC
Relative Strength Index (RSI) 26.44 36.71
Support Level $1.15 $4.05
Resistance Level $1.69 $4.34
Average True Range (ATR) 0.14 0.21
MACD -0.02 0.00
Stochastic Oscillator 3.37 16.71

Price Performance

Historical Comparison
JTAI
BGLC

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: